(BUSINESS WIRE)--Pfizer Inc today announced that Charles E. Triano will join the company as Senior Vice President, Investor Relations, effective June 23. Mr. Triano, who will be responsible for all investor relations functions, including communicating the financial and operational performance of the company with institutional and retail investors, will report directly to Chief Financial Officer Frank D’Amelio.

Since 2000, Triano served as the Vice President of Investor Relations at Forest Laboratories, where he initiated the company’s first formal investor relations and corporate communications program. During his tenure, Forest’s Investor Relations program was twice ranked among the top three programs in the entire healthcare sector by Institutional Investor Magazine, based on a survey of institutional portfolio managers and analysts.

“We are pleased to welcome Chuck to Pfizer,” said Mr. D’Amelio. “As a seasoned investor relations executive who has earned the trust of the investment community and built a highly respected investor relations program, Chuck will be a clear asset to our company. In addition, he brings a deep knowledge of the pharmaceutical industry and its regulatory environment combined with extensive investor relations experience, which will continue to strengthen our relationship with the investment community and our shareholders.”

Prior to joining Forest Laboratories, Triano served as Director of Investor Relations at Bristol-Myers Squibb Company and as Managing Director at The Carson Group (acquired by Thomson Financial in 2000), the shareholder intelligence and investor relations consulting firm.

“I am delighted to join Pfizer, a global leader with a long and storied history of bringing medical innovation to patients and physicians,” Mr. Triano said. “I am eager to begin sharing with investors and shareholders Pfizer’s strategy of accelerating the pipeline and capturing new opportunities for global growth.”

About Pfizer Inc

Founded in 1849, Pfizer is the world's largest research-based pharmaceutical company. Pfizer is taking new approaches to advancing better health as it discovers, develops, manufactures and delivers quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals. Pfizer also partners with healthcare providers, governments and local communities around the world to expand access to medicines and to provide better quality health care and health system support. At Pfizer, approximately 85,000 colleagues in more than 90 countries work every day to help people stay happier and healthier longer and to reduce the human and economic burden of disease worldwide.